메뉴 건너뛰기




Volumn 28, Issue 1, 2008, Pages 74-77

Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

EID: 38349150312     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e3181602cf3     Document Type: Article
Times cited : (21)

References (16)
  • 1
    • 0038653525 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy of secondgeneration antipsychotics
    • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
    • (2003) Arch Gen Psychiatry , vol.60 , pp. 553-564
    • Davis, J.M.1    Chen, N.2    Glick, I.D.3
  • 2
    • 0346120179 scopus 로고    scopus 로고
    • Efficacy and effectiveness of first- and secondgeneration antipsychotics in schizophrenia
    • Jaffe AB, Levine J. Efficacy and effectiveness of first- and secondgeneration antipsychotics in schizophrenia. J Clin Psychiatry. 2003;64(suppl 17):3-6.
    • (2003) J Clin Psychiatry , vol.64 , Issue.SUPPL. 17 , pp. 3-6
    • Jaffe, A.B.1    Levine, J.2
  • 3
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
    • Lieberman JA, Stroup TS, McEvoy JP, et al. for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
    • (2005) N Engl J Med , vol.353 , pp. 1209-1223
    • Lieberman, J.A.1    Stroup, T.S.2    McEvoy, J.P.3
  • 4
    • 34548586774 scopus 로고    scopus 로고
    • Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder
    • Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;64:1163-1171.
    • (2007) J Clin Psychiatry , vol.64 , pp. 1163-1171
    • Dunayevich, E.1    Ascher-Svanum, H.2    Zhao, F.3
  • 5
    • 0035002177 scopus 로고    scopus 로고
    • A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
    • Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-774.
    • (2001) Am J Psychiatry , vol.158 , pp. 765-774
    • Conley, R.R.1    Mahmoud, R.2
  • 6
    • 0030770872 scopus 로고    scopus 로고
    • Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
    • Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-418.
    • (1997) J Clin Psychopharmacol , vol.17 , pp. 407-418
    • Tran, P.V.1    Hamilton, S.H.2    Kuntz, A.J.3
  • 7
    • 23944442440 scopus 로고    scopus 로고
    • Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
    • Dossenbach M, Arango-Davila C, Ibarra HS, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry. 2005;66:1021-1030.
    • (2005) J Clin Psychiatry , vol.66 , pp. 1021-1030
    • Dossenbach, M.1    Arango-Davila, C.2    Ibarra, H.S.3
  • 8
    • 33747185865 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: Observational follow-up study
    • Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224-227.
    • (2006) BMJ , vol.333 , pp. 224-227
    • Tiihonen, J.1    Wahlbeck, K.2    Lonnqvist, J.3
  • 9
    • 33744795750 scopus 로고    scopus 로고
    • Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia
    • Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(suppl 5):3-8.
    • (2006) J Clin Psychiatry , vol.67 , Issue.SUPPL. 5 , pp. 3-8
    • Leucht, S.1    Heres, S.2
  • 11
    • 0036773689 scopus 로고    scopus 로고
    • Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature
    • Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909.
    • (2002) J Clin Psychiatry , vol.63 , pp. 892-909
    • Lacro, J.P.1    Dunn, L.B.2    Dolder, C.R.3
  • 12
    • 3042576182 scopus 로고    scopus 로고
    • Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors
    • Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30:255-264.
    • (2004) Schizophr Bull , vol.30 , pp. 255-264
    • Valenstein, M.1    Blow, F.C.2    Copeland, L.A.3
  • 13
    • 0141841720 scopus 로고    scopus 로고
    • Risk adjustment in studies using administrative data
    • Sernyak MJ, Rosenheck R. Risk adjustment in studies using administrative data. Schizophr Bull. 2003;29:267-271.
    • (2003) Schizophr Bull , vol.29 , pp. 267-271
    • Sernyak, M.J.1    Rosenheck, R.2
  • 14
    • 0036712784 scopus 로고    scopus 로고
    • From conventional to atypical antipsychotics and back: Dynamic processes in the diffusion of new medications
    • Douglas LL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry. 2002;159:1534-1540.
    • (2002) Am J Psychiatry , vol.159 , pp. 1534-1540
    • Douglas, L.L.1    Rosenheck, R.A.2
  • 15
    • 0036773676 scopus 로고    scopus 로고
    • Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder
    • Robinson DG, Woerner MG, Alvir JMJ, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57:209-221.
    • (2002) Schizophr Res , vol.57 , pp. 209-221
    • Robinson, D.G.1    Woerner, M.G.2    Alvir, J.M.J.3
  • 16
    • 0036187764 scopus 로고    scopus 로고
    • Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996
    • Mojtabai R, Lavelle J, Gibson PJ, et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv. 2002;53:337-339.
    • (2002) Psychiatr Serv , vol.53 , pp. 337-339
    • Mojtabai, R.1    Lavelle, J.2    Gibson, P.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.